# Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

> **NCT06514313** · PHASE2 · RECRUITING · sponsor: **Yizhuo Zhang** · enrollment: 110 (estimated)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
- **DRUG:** Temozolomide+Irinotecan+Vincristine

## Key facts

- **NCT ID:** NCT06514313
- **Lead sponsor:** Yizhuo Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514313, "Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06514313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*